nerlynx
(neratinib)Puma Biotechnology, Inc.
Usage: NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer after trastuzumab therapy. It is also used in combination with capecitabine for adults with advanced or metastatic HER2-positive breast cancer who have previously received multiple anti-HER2 regimens.